Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Key Clinical Message: Rituximab-induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.
View Article and Find Full Text PDFRituximab-induced mucosal pyogenic granuloma.
Int J Dermatol
December 2023
Department of Dermatology, University of Gaziantep Faculty of Medicine, Gaziantep, Turkey.
Rituximab-Induced Colitis and Esophagitis in a Patient With Granulomatosis With Polyangiitis.
Cureus
April 2023
Pathology, Jersey City Medical Center, Jersey City, USA.
Granulomatosis with polyangiitis (GPA) is a small vessel vasculitis that affects many organ systems with varying disease severity. GPA commonly affects the sinuses and lung parenchyma. However, GPA can affect the gastrointestinal tract and may present as colitis.
View Article and Find Full Text PDFRituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review.
Intern Med
April 2021
Department of Gastroenterology, Saitama Medical University, Japan.
Rituximab (RTX) is effective for treating cancer, but reports of RTX-associated enterocolitis are limited. We herein report the case of a 65-year-old man who developed RTX-induced ileocolitis. He was diagnosed with gastric mucosa-associated lymphoid tissue lymphoma (MALToma) and treated with RTX.
View Article and Find Full Text PDFOral Lichenoid Reaction: An Uncommon Side Effect of Rituximab.
Case Rep Dent
November 2019
School of Dentistry, Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Oral lichenoid reactions (OLR) can be caused by systemic drug exposure. To the best of our knowledge, this is the second report describing a case of OLR induced by rituximab administration in a patient with a diagnosis of non-Hodgkin B-cell lymphoma. After 5 doses of rituximab, a typical pattern of OLP was identified with bilateral and symmetrical lesions on the buccal mucosa and on the right lingual margin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!